How have PPH shares performed in 2024?

VanEck Pharmaceutical ETF's stock was trading at $81.37 on January 1st, 2024. Since then, PPH stock has increased by 7.1% and is now trading at $87.11. View the best growth stocks for 2024 here .

Are investors shorting VanEck Pharmaceutical ETF?

VanEck Pharmaceutical ETF saw a decrease in short interest in March. As of March 31st, there was short interest totaling 8,700 shares, a decrease of 99.4% from the March 15th total of 1,570,000 shares. Based on an average trading volume of 128,200 shares, the short-interest ratio is presently 0.1 days. View VanEck Pharmaceutical ETF's Short Interest .

How often does VanEck Pharmaceutical ETF pay dividends? What is the dividend yield for VanEck Pharmaceutical ETF?

VanEck Pharmaceutical ETF declared a dividend on Thursday, March 28th. Shareholders of record on Tuesday, April 2nd will be given a dividend of $0.5328 per share on Friday, April 5th. The ex-dividend date of this dividend is Monday, April 1st. Read our dividend analysis for PPH .

What does PPH invest in?

VanEck Pharmaceutical ETF is a equity fund issued by Van Eck. PPH focuses on health care investments and follows the Market Vectors US Listed Pharmaceutical 25 Index. The fund's investments total to approximately $512.72 million assets under management.

What stocks does VanEck Pharmaceutical ETF hold?

PPH invests in 26 holdings. Some of the stocks in their portfolio include Eli Lilly and Company (LLY) , Novo Nordisk A/S (NVO) , Johnson & Johnson (JNJ) , Merck & Co., Inc. (MRK) , AbbVie (ABBV) , AstraZeneca (AZN) , Cencora (COR) , McKesson (MCK) , Haleon (HLN) and Sanofi (SNY) .

What is the management fee for VanEck Pharmaceutical ETF?

VanEck Pharmaceutical ETF's management fee is 0.35% and has no other recorded expenses or fee waivers. The net expense ratio for PPH is 0.35%.

What is Bruce Gordon's approval rating as VanEck Pharmaceutical ETF's CEO?

38 employees have rated VanEck Pharmaceutical ETF Chief Executive Officer Bruce Gordon on Glassdoor.com . Bruce Gordon has an approval rating of 98% among the company's employees. This puts Bruce Gordon in the top 20% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of VanEck Pharmaceutical ETF own?

Based on aggregate information from My MarketBeat watchlists, some companies that other VanEck Pharmaceutical ETF investors own include Bank of America (BAC) , Alibaba Group (BABA) , AeroVironment (AVAV) , Activision Blizzard (ATVI) , ARK Innovation ETF (ARKK) , Applied Materials (AMAT) , Applied Graphene Materials (AGM) , Air Canada (AC) and Abbott Laboratories (ABT) .

Who are VanEck Pharmaceutical ETF's major shareholders?

VanEck Pharmaceutical ETF's stock is owned by many different institutional and retail investors. Top institutional shareholders include Commonwealth Equity Services LLC (0.37%), GSA Capital Partners LLP (0.32%), Raymond James Financial Services Advisors Inc. (0.30%), Mirae Asset Global Investments Co. Ltd. (0.25%), Aspiriant LLC (0.10%) and Conservest Capital Advisors Inc. (0.09%).

How do I buy shares of VanEck Pharmaceutical ETF?

Shares of PPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:PPH

VanEck Pharmaceutical ETF (PPH) Price, Holdings, & News

→ Elon’s New Device is About to Shock the World (From InvestorPlace) (Ad)

Free PPH Stock Alerts

$87.11

-0.30 (-0.34%)

(As of 05/3/2024 ET)

Compare

Today's Range: $86.76
▼
$87.66
50-Day Range: $84.87
▼
$90.89
52-Week Range: $74.05
▼
$91.16

Volume: 111,114 shs
Average Volume: 140,129 shs
Market Capitalization: $517.43 million

Assets Under Management: $512.72 million
Dividend Yield: 1.79%
Net Expense Ratio: 0.35%

Get VanEck Pharmaceutical ETF alerts:

About VanEck Pharmaceutical ETF (NASDAQ:PPH)

The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck.

PPH Stock Price History

30 days | 90 days | 365 days | Advanced Chart

PPH ETF News Headlines

April 23, 2024 | seekingalpha.com

PPH: Buy The Pullback In This Big Pharma ETF For Long-Term Total Returns

April 18, 2024 | theglobeandmail.com

Canada’s updated guidance on ESG-related investment fund disclosure

May 4, 2024 | InvestorPlace (Ad)

Elon’s New Device is About to Shock the World

Using this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.”

April 3, 2024 | msn.com

VanEck Pharmaceutical ETF declares quarterly distribution of $0.5328

April 1, 2024 | msn.com

VanEck Vectors Pharmaceutical ETF declares quarterly distribution of $0.5328

March 7, 2024 | investorplace.com

The Top 3 ETFs to Buy in March 2024

February 28, 2024 | markets.businessinsider.com

11 'Granolas' Stocks Outperform Magnificent 7 With Lower Volatility, Higher Yields

February 28, 2024 | stocknews.com

Navigate to Success With These 4 Pharma Stocks to Buy

May 4, 2024 | InvestorPlace (Ad)

Elon’s New Device is About to Shock the World

Using this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.”

February 26, 2024 | investorplace.com

The 3 Hottest Healthcare ETFs to Buy in 2024

See More Headlines

Receive PPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for VanEck Pharmaceutical ETF and its competitors with MarketBeat's FREE daily newsletter.

Fund Details

Issuer: Van Eck
Fund Name: VanEck Pharmaceutical ETF
Tax Classification: Regulated Investment Company
Stock Exchange: NASDAQ
Current Symbol: NASDAQ:PPH
Inception Date: 12/20/2011
Fund Manager: Hao-Hung Peter Liao, Guo Hua Jason Jin
Web: N/A
Phone: 14089961010

Fund Focus

Asset Class: Equity
Benchmark: Market Vectors US Listed Pharmaceutical 25 Index
Category: Sector
Focus: Health Care
Development Level: Developed Markets
Region: Global
Number of Holdings: 26

Fund Statistics

Assets Under Management: $512.72 million
Average Daily Volume: $164,700.60
Discount/Premium: 0.03%

Administrator, Advisor and Custodian

Administrator: Van Eck Associates Corporation
Advisor: Van Eck Associates Corporation
Custodian: State Street Bank and Trust Company
Distributor: Van Eck Securities Corporation
Transfer Agent: State Street Bank and Trust Company
Trustee: N/A
Lead Market Maker: IMC

Options

Optionable: Optionable
Options Volume: 10
Put Options: 3
Call Options: 10
Short Interest: 1,400,000 shs

Miscellaneous

Outstanding Shares: 5,940,000
Beta: 0.72
Creation Unit: 50,000
Creation Fee: $500.00

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Ad Awesomely, LLC

Automatic Income (from home)

For over 22 years, Wall Street elites have kept this little-known "income hack" from everyday investors… 6 simple clicks have set up HUGE payouts for "in-the-know" investors… Delivering them passive income 365 days a year.

Just click here now to watch my presentation for free.

VanEck Pharmaceutical ETF Expenses

Type	PPH	Health Care ETFs	Equity ETFs	NASDAQ ETFs	All ETFs
Management Fee	0.35%	0.56%	0.54%	0.48%	0.51%
Other Expenses	0.00%	0.40%	0.54%	0.34%	0.58%
Total Expense	0.35%	0.72%	0.70%	0.58%	0.70%
Fee Waiver	0.00%	-0.53%	-0.55%	-0.22%	-0.57%
Net Expense	0.35%	0.60%	0.60%	0.54%	0.58%

VanEck Pharmaceutical ETF (PPH) Holdings & Exposure

Top 10 PPH Holdings

PPH Sector Exposure

PPH Industry Exposure

Full Holdings Details

Similar ETFs

Institutional Ownership

View All Institutional Transactions

PPH ETF - Frequently Asked Questions

How have PPH shares performed in 2024?: VanEck Pharmaceutical ETF's stock was trading at $81.37 on January 1st, 2024. Since then, PPH stock has increased by 7.1% and is now trading at $87.11.
View the best growth stocks for 2024 here.
Are investors shorting VanEck Pharmaceutical ETF?: VanEck Pharmaceutical ETF saw a decrease in short interest in March. As of March 31st, there was short interest totaling 8,700 shares, a decrease of 99.4% from the March 15th total of 1,570,000 shares. Based on an average trading volume of 128,200 shares, the short-interest ratio is presently 0.1 days.
View VanEck Pharmaceutical ETF's Short Interest.
How often does VanEck Pharmaceutical ETF pay dividends? What is the dividend yield for VanEck Pharmaceutical ETF?: VanEck Pharmaceutical ETF declared a dividend on Thursday, March 28th. Shareholders of record on Tuesday, April 2nd will be given a dividend of $0.5328 per share on Friday, April 5th. The ex-dividend date of this dividend is Monday, April 1st.
Read our dividend analysis for PPH.
What does PPH invest in?: VanEck Pharmaceutical ETF is a equity fund issued by Van Eck. PPH focuses on health care investments and follows the Market Vectors US Listed Pharmaceutical 25 Index. The fund's investments total to approximately $512.72 million assets under management.
What stocks does VanEck Pharmaceutical ETF hold?: PPH invests in 26 holdings. Some of the stocks in their portfolio include Eli Lilly and Company (LLY), Novo Nordisk A/S (NVO), Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), AbbVie (ABBV), AstraZeneca (AZN), Cencora (COR), McKesson (MCK), Haleon (HLN) and Sanofi (SNY).
What is the management fee for VanEck Pharmaceutical ETF?: VanEck Pharmaceutical ETF's management fee is 0.35% and has no other recorded expenses or fee waivers. The net expense ratio for PPH is 0.35%.

What is Bruce Gordon's approval rating as VanEck Pharmaceutical ETF's CEO?: 38 employees have rated VanEck Pharmaceutical ETF Chief Executive Officer Bruce Gordon on Glassdoor.com. Bruce Gordon has an approval rating of 98% among the company's employees. This puts Bruce Gordon in the top 20% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of VanEck Pharmaceutical ETF own?: Based on aggregate information from My MarketBeat watchlists, some companies that other VanEck Pharmaceutical ETF investors own include Bank of America (BAC), Alibaba Group (BABA), AeroVironment (AVAV), Activision Blizzard (ATVI), ARK Innovation ETF (ARKK), Applied Materials (AMAT), Applied Graphene Materials (AGM), Air Canada (AC) and Abbott Laboratories (ABT).
Who are VanEck Pharmaceutical ETF's major shareholders?: VanEck Pharmaceutical ETF's stock is owned by many different institutional and retail investors. Top institutional shareholders include Commonwealth Equity Services LLC (0.37%), GSA Capital Partners LLP (0.32%), Raymond James Financial Services Advisors Inc. (0.30%), Mirae Asset Global Investments Co. Ltd. (0.25%), Aspiriant LLC (0.10%) and Conservest Capital Advisors Inc. (0.09%).
How do I buy shares of VanEck Pharmaceutical ETF?: Shares of PPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PPH) was last updated on 5/4/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial